高危患者高血压的治疗选择。
Treatment options for hypertension in high-risk patients.
作者信息
Tsai Wei-Chuan
机构信息
Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
出版信息
Vasc Health Risk Manag. 2011;7:137-41. doi: 10.2147/VHRM.S11235. Epub 2011 Mar 9.
Abstract
Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials.
摘要
如果患者患有糖尿病、慢性肾病、中风、已确诊的冠状动脉疾病或冠状动脉疾病等效症，则被认为具有心血管事件的高风险。降压治疗已被证明能显著降低这些患者的心血管事件。建议对每位高血压患者进行全球风险评估以识别高风险患者。根据目前的临床试验，使用血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂治疗高危患者的高血压，无论是否加用二氢吡啶类钙通道拮抗剂，都是一种合理的方法。
相似文献
1
Treatment options for hypertension in high-risk patients.
Vasc Health Risk Manag. 2011;7:137-41. doi: 10.2147/VHRM.S11235. Epub 2011 Mar 9.
2
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
Can J Cardiol. 2010 May;26(5):249-58. doi: 10.1016/s0828-282x(10)70379-2.
3
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.
Vasc Health Risk Manag. 2011;7:209-35. doi: 10.2147/VHRM.S9434. Epub 2011 Mar 31.
4
Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
Can J Cardiol. 2004 Aug;20 Suppl B:77B-82B.
5
Cardiovascular protection paradigms: is change on the horizon?
Rev Cardiovasc Med. 2007 Fall;8(4):200-13.
6
Treating essential hypertension. The first choice is usually a thiazide diuretic.
Prescrire Int. 2014 Sep;23(152):215-20.
7
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
Vasc Health Risk Manag. 2009;5(1):411-27. doi: 10.2147/vhrm.s4235.
8
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Can J Cardiol. 2004 Jan;20(1):41-54.
9
Combination therapy for hypertension.
Nat Rev Cardiol. 2009 Apr;6(4):270-1. doi: 10.1038/nrcardio.2009.31.
10
HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
High Blood Press Cardiovasc Prev. 2015 Jun;22(2):165-72. doi: 10.1007/s40292-015-0091-6. Epub 2015 Apr 22.
引用本文的文献
1
Comparing Triple Combination Drug Therapy and Traditional Monotherapy for Better Survival in Patients With High-Risk Hypertension: A Systematic Review.
Cureus. 2023 Jul 5;15(7):e41398. doi: 10.7759/cureus.41398. eCollection 2023 Jul.
2
Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial.
J Hum Hypertens. 2017 Mar;31(3):178-188. doi: 10.1038/jhh.2016.54. Epub 2016 Aug 11.
3
The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy.
PLoS One. 2014 Mar 19;9(3):e92216. doi: 10.1371/journal.pone.0092216. eCollection 2014.
本文引用的文献
1
Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.
Lancet. 2011 Jan 22;377(9762):312-20. doi: 10.1016/S0140-6736(10)62003-X. Epub 2011 Jan 12.
2
2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension.
J Formos Med Assoc. 2010 Oct;109(10):740-73. doi: 10.1016/S0929-6646(10)60120-9.
3
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
Vasc Health Risk Manag. 2010 Aug 9;6:549-59. doi: 10.2147/vhrm.s11816.
4
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.
5
Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients.
Hypertension. 2010 Apr;55(4):819-31. doi: 10.1161/HYPERTENSIONAHA.108.122879. Epub 2010 Mar 8.
6
New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease.
Hypertens Res. 2010 Apr;33(4):279-87. doi: 10.1038/hr.2010.19. Epub 2010 Mar 5.
7
When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal.
J Hypertens. 2009 May;27(5):923-34. doi: 10.1097/HJH.0b013e32832aa6b5.
8
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.
9
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29.
10
Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?
Curr Opin Nephrol Hypertens. 2008 Sep;17(5):484-90. doi: 10.1097/MNH.0b013e32830baa9b.
Zotero 插件